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Original Article
Abstract
Purpose: Focal nodular hyperplasia (FNH), a benign hepatic tumor with ill-defined etiology, has been increasingly reported in
children treated for extra-hepatic malignancies. Serial imaging or biopsy may be needed when survivors present with liver le-
sions. This study aims to review the literature, compare them with our institution’s cohort and propose a less invasive diagnostic
imaging modality for FNH utilizing Magnetic resonance imaging (MRI) with gadoxetate disodium. Methods: We reviewed 13
case reports/series published over the last 20 years and compared them to our retrospective review of 16 childhood cancer sur-
vivors (CCS) found to have liver lesions on various imaging studies. Several patients underwent biopsy for diagnosis. Results: No
specific generalizations could be made in terms of which specific chemotherapeutic agents cause FNH. Seven out of 11 patients
underwent radiotherapy and/or hematopoietic stem cell transplant. Additionally, 36% (4/11) had been treated for neuroblastoma.
From the literature review, the use of MRI with gadoxetate disodium was difficult to evaluate. Imaging was mainly accomplished
using ultrasound, computerized tomography and MRI with gadolinium. The results were often indeterminate and resulted in
biopsy in 6 cases in our institution. In contrast, 5 patients underwent initial MRI with gadoxetate disodium, which confirmed the
diagnosis of FNH. Conclusion: CCS have an increased risk of developing liver lesions. Consistent with previously published
literature, patients exposed to radiotherapy or cytoreductive agents used for hematopoietic stem cell transplants appeared to be at
higher risk. A significant proportion (36%, 4/11) of our patients with FNH was previously treated for neuroblastoma. With the
introduction of MRI with gadoxetate disodium, imaging may be a viable alternative to biopsy.
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Introduction
Focal nodular hyperplasia (FNH) is a benign hepatic tumor of
epithelial origin and is the most common benign
non-vascular tumor of the liver.1 Its incidence is second only
to hepatic hemangioma, which is the most common benign
liver tumor of infancy. The classic population affected by
FNH is middle-aged females; the condition is rare in pediatric
populations.1, 2 However, increases in the frequency of rou-
tine imaging studies such as abdominal ultrasound, comput-
erized tomography (CT) and magnetic resonance imaging
(MRI) scans have resulted in an increased identification of
these lesions, often considered an incidental finding. Hepatic
FNH may be associated with vague abdominal symptoms or
elevation in liver enzymes, but they are usually found with-
out other corollary abnormalities.3
Although the etiology of FNH is unknown, a relationship to
oral contraceptive (OCP) use and vascular abnormalities has
been suggested.2 History of cytoreductive chemotherapy
including busulfan and melphalan total body irradiation and
high dose chemotherapy have also been proposed as possible
risk factors as FNH has been seen at increased frequency in
long-term survivors of childhood malignancies.4 In particular,
chemotherapies such as cyclophosphamide and dactinomycin
that induce hepatic vascular endothelial injury or
veno-occlusive disease appear to increase the risk of devel-
oping FNH as a delayed complication.5
These chemotherapeutic agents are often used in the treat-
ment of pediatric solid tumors such as germ cell tumor,
Wilms’tumor, sarcomas and neuroblastoma. One study placed
the incidence of FNH in post-chemotherapy pediatric pa-
tients at 5.1% (versus 0.045% in the general pediatric popu-
lation).5 Certain malignancies appear to confer a higher risk of
developing FNH than others, including medulloblastoma,
malignancies treated with hematopoietic stem cell transplant
and notably, neuroblastoma.2, 4, 6 One study placed the inci-
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dence of FNH in pediatric patients post-hematopoietic stem
cell transplant as high as 12% (17/138).1 However, few au-
thors have explored the development of FNH in the context
of specific oncologic therapy in this patient population.
Diagnosis of hepatic FNH is based on radiographic imaging,
with confirmatory biopsy when necessary. Lesions may be
single or multiple and may vary in size. Significantly, it has
been noted that FNH in children post-oncologic therapy have
a higher incidence of atypical features on imaging including
multiple lesions and lack of the classic central scar.7 Histo-
logical findings on biopsy specimens include a nodule com-
posed of benign-appearing hepatocytes. Typically, hepatic
FNH lesions have large arterial supplies and fibrous stroma
that form prominent stellate scars.8 Diagnosticians must dif-
ferentiate these lesions from metastatic liver lesions or de
novo hepatocellular carcinoma (HCC).
Here, we review the literature on pediatric focal nodular
hyperplasia. We also sought to compare findings from our
cohort of long-term cancer survivors with hepatic focal nod-
ular hyperplasia against data from published literature. We
postulate a mechanism that may augment our understanding
of liver FNH etiology as there is scarcity of knowledge on this
topic in the literature. Our paper will not alter currently
recommended follow-up care of patients with FNH lesions.
However, it is hoped that it will help advance knowledge of
FNH pathogenesis as a possible iatrogenic effect of cancer
therapy. In addition, we report our institution’s experience
with a hepatocyte-specific MRI agent, gadoxetate disodium,
as an alternative option to biopsy in differentiating FNH from
other lesions.
Methods and Materials
We conducted a review of case reports/series published over
the last twenty years (N = 75 pediatric patients with FNH) and
did a retrospective analysis of long term survivors of pediatric
cancers found to have liver nodules from our institution’s
database (N = 16).
Out of the sixteen patients who were evaluated in our insti-
tution between 2001 and 2013, eleven patients (11/16) with
hepatic FNH were identified. Demographic and clinical data
were abstracted from each patient’s medical records, includ-
ing malignancy diagnosis, age at diagnosis, type of therapy
used, duration of therapy, co-morbid conditions and duration
of time between end of treatment and diagnosis of liver le-
sions. Imaging studies, including ultrasound, computerized
tomography, and magnetic resonance imaging with gadolin-
ium were reviewed by our board-certified pediatric radiolo-
gist. Of the eleven patients with FNH, six underwent biopsy
for further characterization of their lesions.
The biopsies were performed prior to our institution’s use of
gadoxetate disodium. Eventually, all eleven patients under-
went imaging using gadoxetate disodium which confirmed
FNH. Follow-up analysis was determined on a case-by-case
basis but typically included repeat imaging after 3 months (N
= 8 out of 16) and liver function tests. Data from our patients
and from those published in the literature were compiled and
analyzed for trends.
Clinical characteristics of the patients are summarized in
Table 1.
TABLE 1: CCS found to have liver lesions from our institutional cohort.
Pt Sex Diagnosis Adjuvant therapy Interval (yrs) Imaging # of lesions Biopsy FNH
1 F PNET XRT/BMT 13 US, CT, MRI-G multiple n/a No
2 M Langerhans Cell
Histiocytosis
XRT 5.6 US, CT, MRI-G 3 n/a No
3 M Neuroblastoma, IV XRT/BMT 7.9 US, CT, MRI-G 3 Yes Yes
4 M Germ Cell Tumor None 13.5 US, MRI-G 1 No No
5 F Neuroblastoma, III TBI/BMT 9 US, CT, MRI-G 6 Yes Yes
6 M Neuroblastoma, IV XRT/BMT 1.3 US, CT 3 No Yes
7 F Germ Cell Tumor None 10.5 US, MRI-E 1 No Yes
8 M Congenital Medul-
loblastoma
XRT/BMT 6.6 US, CT, MRI-G, multiple Yes Yes
9 F Neuroblastoma, IV XRT/BMT 4.6 US, CT 1 Yes Yes
10 F ALL None 2.3 PET/CT, MRI-G multiple Yes No
11 M Wilms Tumor, III None 4.3 US, CT, MRI-G 1 Yes No
12 F PNET XRT/BMT 10 CT 1 No Yes
13 F Ewing's sarcoma XRT .6 CT, MRI-E multiple No Yes
14 F Germ Cell Tumor None 0 CT, MRI-E 1 No Yes
15 F Hepatoblastoma, IV Liver transplant .25 MRI-E 1 No Yes
16 F Rhabdomyosarcoma None 6 MRI-E 1 No Yes
MRI-G = MRI-Gadolinium; MRI-E = MRI-Gadoxetate disodium; Interval years = Time from end of treatment to diagnosis of liver lesions.
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TABLE 2: Therapeutic exposures of patients who developed FNH.
Patient Sex Diagnosis Chemotherapy BMT Prep. Regimen XRT Site VOD
3 M Neuroblastoma Stage IV VCR/CPM/Doxorubicin
Cis-Retinoic acid
Chimeric 14.18/Interleukin2
Carboplatin
Etoposide
Retroperito-
neum
N
5 F Neuroblastoma Stage III VCR/Adriamycin/CPM
Cisplatin/Etoposide Topotecan
Anti-Idiotype Vaccine
Cis-Retinoic acid
Carboplatin
Melphalan
Etoposide
MIBG therapy
TBI
N
6 M Neuroblastoma  Stage IV VCR/Etoposide/Doxorubicin
CPM/Cisplatin
Carboplatin Etoposide Retroperito-
neum
N
7 F Germ cell Tumor Cisplatin/Etoposide
Bleomycin
N N N
8 M Congenital Medulloblastoma Carboplatin/ Cisplatin/ CPM
Etoposide/Temozolomide VCR
Thiotepa Cranial N
9 F Neuroblastoma Stage IV VCR/Etoposide/Doxorubicin
CPM/Cisplatin
Carboplatin
Etoposide
TBI N
12 F PNET VCR/Doxorubicin/CPM
Ifosfamide/Etoposide Carboplatin
CPM
Etoposide
Cranial N
13 F Ewing’s Sarcoma VCR/Doxorubicin
CPM/Ifosfamide
Etoposide/Carboplatin
N Y N
14 F Germ Cell Tumor Cisplatin/Etoposide Bleomycin N N N
15 F Hepatoblastoma 5FU/VCR/Cisplatin N N N
16 F Rhabdomyosarcoma VCR/Dactinomycin/CPM N Y N
VCR = Vincristine; CPM = Cyclophosphamide; MIBG = Iodine-131 meta-iodo-benzylguanidine; TBI = Total body irradiation; PNET = Primitive
neuroectodermal tumor; 5 FU = Fluorouracil
Results
Summary of Observations
A review of our institution’s cohort and case series/reports published in the literature within the last 20 years, identified 75 total
patients with hepatic FNH (34 boys and 41 girls; mean age at initial cancer diagnosis 5.7 years; mean number of years between
diagnosis of primary malignancy OR bone marrow transplant and diagnosis of FNH, approximately 8.75 years). Of the 75 total
patients we analyzed with FNH, 64 patients (64/75) were found on literature review. Analysis of our institution’s database of
pediatric cancer long-term survivors yielded sixteen patients with liver lesions. Eleven of these patients were diagnosed with
FNH.
FIG. 1: 14 year old female with rhabdomyosarcoma of cervix. Hypodense right lobe liver lesion found on surveillance CT (not shown). Left image
shows axial MRI of the abdomen, T1 arterial phase after administration of gadoxetate disodium. (curved arrow) Enhancing mass segment 6 of the
liver. Right image shows axial MRI abdomen. T1 hepatobiliary phase, 20 minute delay after gadoxetate disodium administration. (yellow arrows)
The mass retains enhancement equal to or slightly greater than background liver. Findings are consistent with FNH.
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FIG. 2: 10 year old male with medulloblastoma. MRI of lumbar spine for surveillance showed right lobe liver lesion. Upper left image shows axial
MRI of the abdomen, T1 pre contrast. (curved arrow) Slightly T1 hypointense mass segment 7 of the liver. Upper right image shows axial MRI
abdomen T2 fat sat pre contrast. (asterisk) The mass is slightly T2 hyperintense compared to liver background. Left lower image shows T1 arterial
phase after gadoxetate disodium. (yellow arrows) Mass shows enhancement. Right lower image shows T1 sequence hepatobiliary phase, 20
minute delay after gadoxetate disodium administration. (yellow arrow) The mass retains enhancement greater than background liver. Findings
are consistent with FNH. Note central scar.
In more detail, in our cohort, 12/16 patients underwent MRI
following discovery of hepatic lesions on US or CT. Of these
12 patients, 7 had MRI with gadolinium and 5 had initial MRI
with gadoxetate disodium. Figures 1 and 2 show representa-
tive images of FNH noted after gadoxetate disodium at our
institution. Among patients who were imaged using gado-
linium, 5 required biopsy due to indeterminate findings
whereas none of those who initially received gadoxetate
disodium had to be biopsied because of diagnostic findings.
The results of the biopsies showed benign regenerative tissue
(3), benign fatty liver (1), spindle cell neoplasm (1) and 1 was
indeterminate. None of those who were initially imaged with
gadoxetate disodium had to be biopsied because of highly
characteristic findings using gadoxetate disodium. Patient 9
underwent biopsy after CT imaging alone based on the
treating physician’s decision. Patient 8 underwent biopsy
after gadolinium imaging due to inconclusive results. This
occurred prior to our institutional use of gadoxetate disodium
contrast. Pathology showed benign fatty liver. He subse-
quently underwent MRI with gadoxetate disodium once the
contrast became available at our institution, and this revealed
characteristic findings of FNH.
Consistent with previously published literature, a significant
proportion of our patient population had been treated for
neuroblastoma (4/11). These patients received cisplatin,
etoposide, cyclophosphamide, doxorubicin and carboplatin,
which are agents commonly used for solid tumors. None
developed veno-occlusive disease during treatment. Seven
out of eleven patients underwent radiotherapy and/or hem-
atopoietic stem cell transplant. Just over half (6/11) of our
patients had multiple foci of FNH. No significant generaliza-
tions could be made in terms of specific causative chemo-
therapy agents, history of veno-occlusive disease or the
presence or absence of graft versus host disease. Imaging
techniques used at outside institutions could not be evaluated
due to insufficient reporting.
Discussion
Hepatic FNH lesions are considered a result of a hyperplastic
rather than a neoplastic process. Classically, FNH forms a
nodular lesion characterized by a central stellate scar with
malformed vascular structures and thickened hepatic plates
that form radiating fibrous septa (Figures 1 & 2).9 These
changes have a characteristic radiologic appearance by MRI
with gadoxetate disodium. In a study examining 305 con-
firmed cases of FNH, Nguyen et al. reported that FNH lesions
were well-limited from the surrounding liver, implying a
regional rather than a global hepatic insult.10 Lough et al.
presented indirect evidence of regional circulatory disturb-
ances and proposed that thrombosis might result in vascular
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narrowing leading to FNH.11 Additionally, Kumagai et al.
showed direct evidence of arterial and portal thrombi and
recanalization of arteries in a nodule.12 They postulated that
hepatic arterial recanalization and tissue perfusion following
a thrombotic ischemic event results in changes consistent
with the radiologic stellate appearance.12 The stellate scar is
likely the end-stage of progressive sclerosis or thrombosis of
vascular malformation.13
Results from earlier studies emphasized the high prevalence
of neuroblastoma and germ cell tumors among patients di-
agnosed with FNH.2 This was similarly shown in our patient
cohort. Majority of these children are treated with varying
combinations of high dose chemotherapy, however, the oc-
currence of FNH may be linked to the nature and intensity of
the treatment rather than the histologic diagnosis.
Ruling out malignant hepatic lesions is particularly important
in patients previously treated for malignancy. Historically,
diagnosis has relied on imaging studies that utilize radiation,
such as CT, and/or invasive techniques such as biopsy. The
elevated incidence of FNH with atypical features, especially
lack of central scar and multiplicity, emphasizes the need for
ideal diagnostic imaging methods.
Fortunately, recent advancements in imaging technology
have yielded greater accuracy when diagnosing with imaging
alone. Ultrasound, CT, as well as MRI with traditional ex-
tracellular gadolinium agents each have limitations in dif-
ferentiating FNH (a benign lesion) from other hepatic lesions
that require treatment. Ultrasound features of FNH are not
specific and do not allow differentiation from other hepatic
lesions.14 On dynamic contrast-enhanced CT, FNH exhibits
isoattenuation on precontrast phase, hyperattenuation during
the arterial phase, and isoattenuation on the portal venous
phase. This pattern is referred to as a “stealth” appearance, as
enhancement is only seen on the arterial phase and, on pre-
contrast images, the lesion blends into background liver at-
tenuation. A portion of these lesions demonstrates a central
scar but this is also seen in hepatic adenoma, fibrolamellar
hepatocellular carcinoma, giant hemangiomas, and others.
Despite the superior soft tissue contrast of MRI as compared
to CT, MR signal patterns of FNH and central scar are unre-
liable and may appear atypical, ultimately requiring biopsy
for a definitive diagnosis.15
Because FNH is essentially a localized abnormal arrangement
of functioning hepatocytes with some biliary elements that
do not connect to the biliary tree, hepatocyte-specific gado-
linium agents have improved the accuracy of diagnosing
FNH. One such agent, gadobenate dimeglumine, Gd-BOPTA,
(Multihance, Bracco Imaging, Milan Italy) was FDA approved
in 2004 and has up to 4% hepatocyte uptake and excretion
into the biliary system. Because of the structure of FNH
mentioned above, the hepatocyte-specific agent has delayed
clearance. On delayed images, FNH is hyperintense or iso-
intense at 1-2 hours to background liver.16 Non-FNH lesions
are hypointense to background liver. Since 2008, another
hepatocyte-specific MRI agent, gadoxetate disodium (Bayer
Health-Care) has been FDA approved and has been used for
the diagnosis of FNH.17 Gadoxetate disodium is transported
into hepatocytes via enterohepatic circulation and is elimi-
nated equally by biliary and renal excretion. Due to the high
level of uptake by hepatocyte and relatively weak binding to
extracellular proteins, hepatocytes will be greatly enhanced
on a T1-weighted image. Gadoxetate disodium also has a high
level of relaxivity, which results in proportional increased
enhancement on T1 weighted image. This allows for gadox-
etate disodium to be dosed at one-quarter the volume (0.025
mmol/kg body weight) of other gadolinium-based contrast
agents.17 Compared to gadobenate dimeglumine
(Gd-BOPTA), gadoxetate disodium only requires 20 min of
delayed imaging to reach the hepatocyte phase. MRI with
gadoxetate disodium now nearly obviates the need for histo-
logic confirmation of FNH, especially when characteristic
features of hepatic FNH are found in patients with low risk
factors for HCC.18 Gadoxetate disodium, which is taken up
only by functioning hepatocytes, is the contrast agent that
produces the greatest specificity.19 Importantly, gadoxetate
disodium also enables physicians to distinguish between FNH
and other liver lesions- including adenoma, HCC, and dys-
plastic nodules- at a high level of accuracy.18 Other recent
studies comparing MRI with gadoxetate disodium to con-
trast-enhanced CT for the differentiation of incidental-
ly-found benign versus malignant hepatic lesions have con-
cluded that MRI with gadoxetate disodium yields higher
accuracy of diagnosis versus CT.9 Authors additionally de-
termined that MRI with gadoxetate disodium is superior for
the radiologic diagnosis of FNH.20 The sensitivity and speci-
ficity of using MRI in healthy children with suspected FNH is
82.6% and 97.4%, respectively.21
Our institutional experience reflects the above findings. Of
the five patients who underwent initial MRI with gadoxetate
disodium, none underwent biopsy. Given this data, an
evolving trend towards the use of hepatocyte-specific con-
trast imaging is emerging as a major diagnostic criterion for
FNH. At this time, it may appear reasonable to suggest im-
aging using hepatocyte-specific agents and clinical picture
alone to diagnose and follow FNH. Furthermore, the use of
imaging with hepatocyte-specific agents may altogether ob-
viate the need for invasive or irradiating techniques in the
work-up of FNH. Once diagnosed, most lesions do not require
treatment unless patients are clearly symptomatic, or lesions
significantly increase in size or if radiological investigations
show signs of intralesional hemorrhage.22
Conclusion
FNH is an uncommon benign hepatic tumor that is most
commonly detected incidentally. Recently, this condition has
been described in increasing frequency among childhood
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cancer survivors. It is important for clinicians to be aware of
this clinical entity as survivors transition into adulthood.
When found in children previously treated for extra-hepatic
malignancies, the need to rule out metastasis is particularly
important. Diagnosis has historically been made using CT and
biopsy. However, with higher accuracy imaging with MRI
with gadoxetate disodium, clinicians now have a viable
non-invasive option to diagnose FNH in this patient popula-
tion. Since FNH rarely causes complications, conservative
management with serial imaging and assessment of liver
function is recommended. In the event of enlargement or
occurrence of symptoms, resection is usually advised.
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